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997CORRESPONDENCE
Controversies in Dermatology
*The Progressing Evidence in AK (PEAK) Working Group, formed to 
identify and address existing educational needs in AK
Actinic keratosis (AK) is a chronic, progressive disease 
of the skin that has undergone long-term sun exposure. 
The affected areas contain visible and subclinical non-
visible sun damage resulting in epidermal keratinocyte 
dysplasia, known by many as ‘field cancerisation’ (1), 
which is prone to AKs and sun-related skin cancer (2). 
Thus, visible AKs are clinical biomarkers for a photo-da-
maged field with subclinical damage associated with the 
unpredictable risk of progression to invasive squamous 
cell carcinoma (iSCC) (3). The aim of this multiexpert 
opinion article is to provide a discussion succinctly 
highlighting the clinical gaps for optimal management of 
AK: the lack of a universal definition and the need for a 
standardised grade assessment of AK/field cancerisation 
that also takes into account individual risk.
The prevalence of AK varies from 6–60%, depen-
ding on age, phototype and other predisposing risk 
factors (most notably immunosuppressed status, out-
door workers), and is increasing (1, 4), with a parallel 
increase in non-melanoma skin cancer (NMSC). AK 
presents a considerable socioeconomic burden, which 
will inevitably increase with an aging population (1, 
4). To minimise this burden, AK should be recognised 
and treated, particularly in populations at high risk of 
NMSC. The goal of therapy should be to eliminate AK/
field cancerisation (visible and non-visible subclinical 
lesions) to minimise risk of AK recurrence and potential 
progression to iSCC (5), although evidence for the lat-
ter is lacking. Some authors in specialised centres have 
shown the additional value of imaging methods in such 
management, particularly in visualising the evolution of 
subclinical lesions, which can be a challenge in current 
clinical practice (2).
Lesion-directed therapy (e.g. cryotherapy), treats only 
visible AKs, so field–directed treatment is necessary to 
treat subclinical damage, reduce AK recurrence rates 
and potentially minimise the risk of iSCC development 
(5). Recent guidelines recognise the importance of trea-
ting the entire field (5–7). However, cryotherapy alone 
remains the standard of care for treating AK patients 
with multiple lesions. This suggests that education, and 
growing evidence that treating the field is equally as 
important as treating visible AKs, will be instrumental 
in reducing the increasing disease burden. Shifting the 
treatment paradigm will require understanding the clini-
cal gaps that need addressing.
Firstly, there is a need for a standardised definition of 
AK field cancerisation in clinical, molecular and histo-
pathological terms. Current guidelines define field can-
cerisation based on number of AK lesions and presence 
of surrounding photo-damaged skin (5–7). However, 
there are wide discrepancies within these criteria (Table 
I). Moreover, experts have voiced concerns over using 
a definition based on AK counts, as existing evidence 
suggests that any AK should be considered a marker of 
field change (8). A clearer and unambiguous definition 
of field cancerisation that is standardised and reprodu-
cible is required to support diagnosis and management, 
including treatment options and identification of ‘red flag’ 
signs of high-risk tumours. Physicians can only manage 
field cancerisation appropriately if they understand its 
characteristics and severity.
A second clinical gap is the lack of a reproducible 
clinical global assessment scale for grading AK/field can-
cerisation. Current guidelines assess only the presence 
or absence of AK/field cancerisation, without a severity 
grading. A global assessment scale should include a clini-
cal description of the key characteristics for each grade 
of severity to guide effectively identification, diagnosis 
and treatment decisions. 
This clinical grading should be considered alongside 
modulating risk factors:
• age
• skin phototype 
• lifestyle
• occupation
• geographical location
• history of skin cancer
• immunosuppression.
Through clinical grading based on disease severity and 
individual patient risk factors, a therapeutic algorithm 
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that enables physicians to make informed treatment 
decisions would be valuable. 
A relevant clinical challenge is the lack of direct 
evidence to date that AK can progress to iSCC, and that 
treating AK may prevent the risk of SCC. This is likely 
to impair the uptake of field therapy despite recommen-
dations by current guidelines. 
However, it seems reasonable to advocate field treat-
ment in appropriate patients based on expert clinical 
judgement supported by: 
• a well-established association between AK/field can-
cerisation and skin cancer (9) 
• emerging evidence that field therapies treat field 
cancerisation (i.e. visible AK lesions and non-visible 
subclinical lesions) (2), and
• preliminary evidence that field therapies prevent SCC 
in animal models (10). 
In summary, addressing the lack of expert consensus on 
the definition and grading of AK/field cancerisation is 
crucial to aid physicians in their decision making and 
optimise appropriate management of AK.
Aiming to address such a need, the authors propose 
to undertake:
• a systematic review of the literature on field cancerisa-
tion to inform a robust definition
• a global assessment scale for grading AK, which ta-
kes into account the entire affected field and not only 
individual AK lesions.
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Table I. Various definitions of field cancerisation
Guideline Year Definition of ‘field cancerisation’
International League of Dermatological Societies/European Dermatology Forum 2015 (5) “At least 6 AK lesions in one body region or field, and contiguous areas 
of chronic actinic sun damage and hyperkeratosis” 
Swiss Registry of Actinic Keratosis Treatment (REAKT) Working Group 2014 (6) “Two or more AKs on photodamaged skin”
Italian expert consensus for the management of actinic keratosis (AK) in 
immunocompetent patients
2016 (7) “…a lesion density ≥ 3/25 cm2 skin field…”
